Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Appoints Seth H.Z. Fischer to its Board of Directors
RADNOR, Pa., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Seth H.Z....
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
RADNOR, Pa., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for...
View HTML
Toggle Summary Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
Anxiety and Hyperactivity Benefit shown in FXS Children Study Investigator to Participate in Conference Call and Webcast Today at 9:00 a.m. ET  RADNOR, Pa., June 28, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of...
View HTML
Toggle Summary Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
RADNOR, Pa., June 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the company will host a conference call and live...
View HTML
Toggle Summary Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
Ganaxolone IV Program Aimed at Status Epilepticus Target Indication...
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
Conference Call Today at 8:00 a.m. ET...
View HTML
Toggle Summary Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference
RADNOR, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it will be participating in the Bank of America Merrill...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results
RADNOR, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for...
View HTML
Toggle Summary Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
Data Presented at the American Academy of Neurology Annual Meeting Phase 1 Clinical Program On-Track to Initiate in 1H 2016 RADNOR, Pa., April 19, 2016 (GLOBE NEWSWIRE) --   Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative...
View HTML
Toggle Summary Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
RADNOR, Pa., April 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S....
View HTML